The continuum between healthy ageing and idiopathic Parkinson Disease within a propagation perspective of inflammation and damage: the search for new diagnostic, prognostic and therapeutic targets.

The continuum between healthy ageing and idiopathic Parkinson Disease within a propagation perspective of inflammation and damage: the search for new diagnostic, prognostic and therapeutic targets. - PROPAG-AGEING - Phase 1

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00009427

Enrollment

15900

Registered

2015-10-22

Start date

2015-09-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G20

Interventions

Group 1: Parkinson Disease patients will be studied by an integrated set of omics (genomics, epigenomics, transcriptomics, metabolomics, proteomics, lipidomics, glycomics). Group 2: Healthy controls w

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: For PD patients: 1. Male and female patients older than 18 years; For healthy controls: 1. Male and female patients older than 18 years; 2. Adhesion to the study after signature of a written informed consent. For long-lived subjects: 1. Subjects >100 years old 2. Siblings >90 years old

Exclusion criteria

Exclusion criteria: For PD patients: 1. Patients with parkinsonian syndromes with different etiology (cerebro-vascular diseases, iatrogenic, infective, malformative or metabolic); For healthy controls: 1. Subjects affected by cardiovascular diseases (coronary heart diseases, previous coronary stenting implantations..); 2. Subjects affected by psychiatric disorders; 3. Subjects affected by systemic, kidney, liver, or pulmonary diseases.

Design outcomes

Primary

Measure	Time frame
To identify biomarkers for early diagnosis of Parkinson disease. This study is a multi-center study intended to perform multi-omic (genomics, epigenomics, transcriptomics, metabolomics, proteomics, lipidomics, glycomics) and validation analysis on samples from PD patients, long-lived subjects and healthy controls already recruited from 1992 to 2014.	—

Secondary

Measure	Time frame
There are no secondary outcomes measures planned at this time	—

Countries

Germany, Italy, Spain, Sweden, United Kingdom

Contacts

Public ContactClaudio Franceschi

IRCCS Istituto dell Scienze Neurologiche di Bologna

c.franceschi@ausl.bologna.it+39 051 4996075

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026